[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ScinnoHub Pharmaceutical Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":135},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,68,91,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100642350","phase-1-study-of-snh-118110-in-advanced-solid-tumors-100642350",false,"NCT07649200","Study of SNH-118110 in Advanced Solid Tumors","A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SNH-118110 in Patients With Advanced Solid Tumors","SNH-118110","Inclusion Criteria:\n\n* Ability to understand and voluntarily sign an informed consent form (ICF) prior to any study related procedures.\n* Age ≥ 18 years at the time of signing the ICF.\n* Histologically or cytologically confirmed diagnosis of advanced solid tumors, with the following additional requirements:\n\nDose-escalation phase: Patients with advanced solid tumors harboring a RET gene alteration who have failed standard therapy or are intolerant to standard therapy.\n\nDose-expansion phase:\n\nCohort 1: Locally advanced or metastatic NSCLC with RET gene fusion who have progressed after at least one prior line of therapy, which must include a RET inhibitor.\n\nCohort 2: Treatment-naïve patients with locally advanced or metastatic NSCLC harboring a RET gene fusion.\n\nCohort 3: Other advanced solid tumors harboring RET gene alterations.\n\n* At least one measurable target lesion according to RECIST version 1.1.\n* Documentation of a RET fusion or other activating RET gene alteration (based on a local or central laboratory report).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with no deterioration within the 2 weeks prior to the first dose of study drug.\n* Life expectancy of at least 3 months.\n\nExclusion Criteria:\n\n* Presence of other known oncogenic driver mutations.\n* Prior anti-tumor therapy within specified washout periods prior to first dose (e.g., small molecules, biologics, radiotherapy, major surgery), or failure to recover from clinically significant toxicities.\n* Clinically significant uncontrolled or active conditions, including but not limited to:\n\nInadequate bone marrow, hepatic, or renal function. Significant cardiovascular disease (e.g., uncontrolled hypertension, prolonged QTc, poor ejection fraction, recent thromboembolic events).\n\nActive or uncontrolled infections, bleeding diathesis, or significant pleural\u002Fabdominal\u002Fpericardial effusion requiring intervention.\n\nCentral nervous system metastases unless stable and asymptomatic off steroids.\n\n* Conditions affecting oral drug absorption or gastrointestinal function.\n* History of severe allergic reactions to similar agents.\n* Pregnant or lactating women, or patients with serious concurrent medical or psychiatric conditions that would compromise safety or study compliance.","ALL","18 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a multicenter, open-label, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SNH-118110 administered orally. The study consists of a dose-escalation phase and a dose-expansion phase.",[27],"Solid Tumors",[29,30,31],"Advanced Solid Tumors","Medullary Thyroid Cancer","Non-Small Cell Lung Cancer","NOT_YET_RECRUITING","2026-06-11",{"date":35,"type":36},"2026-06-16","ACTUAL",{"date":38,"type":21},"2026-06-26",{"date":40,"type":21},"2029-06-26",{"name":42,"class":43},"ScinnoHub Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100639052","phase-2-a-study-of-snh-119014-in-adult-participants-with-non-transfusion-dependent-thalassemia-ntdt-100639052","NCT07579949","A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT)","A Phase 2 Study to Determine the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SNH-119014 in Adult Subjects With Non-transfusion-dependent Thalassemia","Inclusion Criteria:\n\n* Male or Female;\n\n  -≥18 years;\n* Documented diagnosis of thalassemia;\n* Non-transfusion-dependent;\n* Hb concentration ≤10.0 grams per deciliter (g\u002FdL) during the screening period;\n* For women of reproductive potential: negative serum pregnancy test during the screening period;\n* Agreement to use approved contraceptive measures;\n* Informed consent;\n\nExclusion Criteria:\n\n* Hemoglobin S forms of thalassemia;\n* History of Congestive Heart Failure Within 6 months prior to signed informed consent;\n* Myocardial Infarction\u002Funstable angina Within 6 months prior to signed informed consent;\n* Deep Vein Thrombosis\u002Fstroke\u002Fthromboembolic events Within 6 months prior to signed informed consent;\n* Poorly controlled hypertension or diabetes;\n* Markedly abnormal QTcF interval;\n* Severe arrhythmia requiring treatment as assessed by the investigator;\n* Markedly abnormal left ventricular ejection fraction;\n* Diagnosis of any other congenital or acquired hematologic disorder, or any other hemolytic process;\n* Active infection requiring intravenous antibiotics or of Grade ≥3 severity within 4 weeks prior to the first dose;\n* History of primary malignancy, except for: cured non-melanoma skin cancer; curatively treated cervical or breast carcinoma in situ; or other primary tumors treated with curative intent with no known active disease and no treatment in the past 5 years;\n* History of neurological or psychiatric disorders that, in the investigator's assessment, may affect the participant's ability to participate in the clinical study;\n* Post-splenectomy sepsis;\n* Severe pulmonary disease or hepatobiliary disease;\n* Abnormal laboratory tests during screening;\n* Use of luspatercept, hydroxyurea, erythropoietin, strong CYP3A4 inhibitors, or strong CYP3A4 inducers within the prohibited period specified in the protocol;\n* Receipt of anticoagulant therapy prior to screening, or requirement for anticoagulant therapy during the study period;\n* Prior bone marrow or stem cell transplant;\n* Pregnant or lactating women;\n* Major surgery within 6 months prior to signing informed consent or planned during the study period;\n* Splenectomy scheduled during the study treatment period;\n* Participation in another clinical trial and receipt of investigational treatment within 3 months;\n* History of severe allergy, or allergy to SNH-119014 or its excipients;\n* Any other condition that, in the investigator's opinion, makes the participant unsuitable for enrollment.",{"count":53,"type":21},30,[55],"PHASE2","This study is a multicenter study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of treatment with SNH-119014 in adult participants with non-transfusion-dependent thalassemia. 30 participants with non-transfusion-dependent thalassemia were enrolled.",[58],"Thalassemia","2026-05-06",{"date":61,"type":36},"2026-05-12",{"date":63,"type":21},"2026-06-18",{"date":65,"type":21},"2027-04-29",{"name":42,"class":43},8,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":74,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":44},"100605952","phase-1-evaluation-of-safety-efficacy-and-pharmacokinetics-of-bt-114143-injection-in-patients-with-abnormal-uterine-bleeding-100605952","NCT07169214","Evaluation of Safety, Efficacy, and Pharmacokinetics of BT-114143 Injection in Patients With Abnormal Uterine Bleeding","Inclusion Criteria:\n\n1. Be able to sign the informed consent form before any study-related procedures are performed, and be willing and able to comply with the study requirements;\n2. Premenopausal female subjects, aged 18-50 years, including 18 and 50 years;\n3. Have regular menstrual cycles in the past 6 months, with a menstrual cycle of ≥21 days and ≤35 days, and a menstrual period duration of ≤14 days;\n4. Meet the diagnosis of abnormal uterine bleeding and agree to be admitted for treatment. Assessed by the alkaline hemoglobin method, in 2 consecutive menstrual cycles during the screening period, the menstrual blood loss is \\>80 ml in both cycles; or the blood loss in any one cycle is ≥160 ml;\n5. The pregnancy test result is negative before randomization;\n6. Those with a body mass index \\[BMI = weight (kg) \u002F height² (m²)\\] of 18.5-28.0 kg\u002Fm² (including the boundary values).\n\nExclusion Criteria:\n\n1. Patients with known endometrial polyps \\> 1.5 cm, endometrial malignancy, or atypical hyperplasia;\n2. Patients with known or investigator-determined ovulatory dysfunctional abnormal uterine bleeding who require hormonal therapy;\n3. Patients identified by investigators as having iatrogenic abnormal uterine bleeding;\n4. Patients with abnormal uterine bleeding related to coagulation dysfunction, including but not limited to those with laboratory test results showing: platelet count ≤ 100×10⁹\u002FL, or APTT prolonged by ≥ 10s beyond the upper limit of normal, or PT prolonged by ≥ 3s beyond the upper limit of normal;\n5. Patients with bleeding caused by cervical or vaginal lesions;\n6. Patients who have undergone major surgery within 6 months prior to screening;\n7. Patients determined by investigators before randomization to require surgical treatments such as total hysterectomy, myomectomy, hysteroscopic treatment, uterine artery embolization, or ablation during the study period;\n8. Patients who have received the following medications within 3 months prior to randomization: gonadotropin-releasing hormone agonists; sex hormone drugs administered orally, by injection, vaginally, or transdermally (including but not limited to drugs containing estrogen or progesterone); selective estrogen receptor modulators; hormonal intrauterine devices (LNG-IUS). For long-acting (3-month) gonadotropin-releasing hormone agonists or progesterone preparations, the last administration must be no later than 6 months prior to randomization;\n9. Patients who have used danazol, desmopressin, tranexamic acid, aminocaproic acid, or traditional Chinese medicines for the treatment of menorrhagia within 3 months prior to randomization;\n10. Patients who need to receive anticoagulants (e.g., warfarin, heparin, etc.) or antiplatelet therapies (e.g., clopidogrel, ticagrelor, etc.) during the study period;\n11. Patients with intolerance or contraindications to BT-114143 Injection;\n12. Patients who have participated in clinical trials of other investigational drugs, biological agents, or medical devices and received therapeutic interventions within 30 days prior to screening;\n13. Patients with clinically severe diseases such as known disorders of the circulatory, endocrine, nervous, digestive, respiratory, urinary, hematological, immunological, psychiatric, or metabolic systems, as assessed by investigators as unsuitable for participation in the trial;\n14. Patients with a known history of glaucoma or retinopathy, as assessed by investigators as unsuitable for participation in the trial;\n15. Untreated or poorly controlled thyroid dysfunction, except for mild subclinical hypothyroidism (i.e., TSH \\\u003C 10 mIU\u002FL with normal FT4 and TT4);\n16. Patients with a known history of thrombotic diseases, including but not limited to pulmonary embolism, deep vein thrombosis, etc.;\n17. Patients diagnosed with malignant tumors within the past 5 years, except for cured basal cell carcinoma of the skin;\n18. Patients with cervical cytology results indicating a risk of cervical cancer within 1 year prior to the screening period and requiring treatment.\n19. Patients with one or more of the following abnormal laboratory test results before randomization:\n\n    * Alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 1.5 × ULN;\n    * Total bilirubin \\> 1.5 × ULN, except for patients with Gilbert's syndrome;\n    * eGFR ≤ 60 mL\u002Fmin\u002F1.73 m² (calculated using the CKD-EPI formula);\n    * Hemoglobin \\\u003C 90 g\u002FL;\n20. Patients with known infection of human immunodeficiency virus (HIV), or positive hepatitis B surface antigen (HBsAg), or positive hepatitis C virus antibody (HCV Ab);\n21. Alcohol abusers (i.e., consuming more than 14 standard units of alcohol per week within 3 months before screening (1 standard unit contains 14g of alcohol, such as 360ml of beer, 45ml of spirits with 40% alcohol content, or 150ml of wine)), or those with a history of drug abuse (such as morphine, tetrahydrocannabinolic acid, methamphetamine, 3,4-methylenedioxymethamphetamine, ketamine) within 1 year before screening, or with mental or neurological diseases that investigators consider may affect participation in the study;\n22. Pregnant or lactating women, or subjects who had unprotected sex within 14 days before screening;\n23. Subjects who have plans for pregnancy from the time of signing the informed consent form until 3 months after the last administration, or subjects (or their partners) who are unwilling to take effective contraceptive measures (specific contraceptive measures are shown in Appendix 1);\n24. Patients with any condition or result that investigators or designated personnel consider may pose a risk to subjects or the implementation of the study;","FEMALE","50 Years",{"count":77,"type":21},39,[24],"This is a randomized, double-blind, placebo-controlled, multiple-dose escalation, Phase Ib clinical study conducted in patients with abnormal uterine bleeding (e.g., AUB). It aims to evaluate the safety, efficacy, pharmacokinetic characteristics of multiple administrations of BT-114143 Injection at different doses, as well as to explore changes in coagulation-related biomarkers and quality of life.\n\nIt is planned to enroll 39 adult patients with abnormal uterine bleeding.",[81],"Abnormal Uterine Bleeding","RECRUITING","2025-12-12",{"date":85,"type":36},"2025-12-15",{"date":87,"type":36},"2024-10-30",{"date":89,"type":21},"2025-12-31",{"name":42,"class":43},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":44},"100602709","phase-2-study-on-bt-114143-reducing-perioperative-bleeding-in-total-knee-arthroplastytka-100602709","NCT07127042","Study on BT-114143 Reducing Perioperative Bleeding in Total Knee Arthroplasty（TKA）","A Randomized, Double-blind, Active-controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of BT-114143 Injection in Reducing Perioperative Blood Loss in Unilateral Total Knee Arthroplasty","TKA","Inclusion Criteria:\n\n* Aged 18-70 years, regardless of gender (including boundary values);\n* Patients with osteoarthritis who meet the diagnostic criteria of the American College of Rheumatology (ACR), meet the indications for knee replacement, and plan to undergo total knee arthroplasty;\n* American Society of Anesthesiologists (ASA) physical status classification ≤ Grade 3;\n* Patients with mild knee deformity: flexion deformity \\\u003C 20°, varus deformity \\\u003C 15°-5.No abnormalities in preoperative platelet level and coagulation function;\n* Body Mass Index \\[BMI = weight (kg)\u002Fheight² (m²)\\] within the range of 20.0-35.0 kg\u002Fm² (including critical values);\n* Patients voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Uncontrolled systemic or local infections, including but not limited to pulmonary infection, skin infection, urinary tract infection, etc.;\n* Serum albumin concentration \\\u003C 35g\u002FL;\n* Patients with preoperative hemoglobin \\\u003C 110g\u002FL;\n* Patients with a known history of severe venous thromboembolism or those with severe thromboembolic risk indicated by lower extremity venous ultrasound (such as popliteal vein and proximal venous thrombosis);\n* Patients with severe cardiovascular and cerebrovascular diseases (history of myocardial infarction, angina pectoris, stroke, epileptic seizure, subarachnoid hemorrhage, heart failure, etc. within 6 months before screening);\n* Patients with severe varicose veins or severe peripheral arterial diseases affecting distal blood supply (lower extremity arterial stenosis, occlusion);\n* Patients with cancer within 5 years before screening, except for cured skin basal cell carcinoma;\n* Hypertensive patients with poorly controlled blood pressure (SBP ≥ 140mmHg and\u002For DBP ≥ 90mmHg), or those requiring combined use of thiazide diuretics, loop diuretics, potassium-sparing diuretics, etc;\n* Patients with poorly controlled diabetes (fasting blood glucose \\> 8 mmol\u002FL);\n* Patients with known severe history of allergic reactions that may affect the evaluation of the study, or those allergic to tranexamic acid and its similar drugs;\n* Patients who have undergone open knee surgery on the ipsilateral knee (arthroscopic surgery is allowed);\n* Patients planning to undergo other surgeries within 1 month (including simultaneous bilateral total knee arthroplasty);\n* Patients with combined severe liver or kidney dysfunction (eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m², ALT and\u002For AST \\> 2 times the upper limit of normal range);\n* Positive for hepatitis B surface antigen, hepatitis C antibody, HIV antigen\u002Fantibody, or syphilis antibody during screening;\n* Patients who have used drugs affecting coagulation function within 1 week before surgery (such as aspirin, clopidogrel, ticlopidine, dipyridamole, ginkgo biloba preparations, heparin, warfarin, citrate, hemocoagulase, vitamin K, antifibrinolytic agents, etamsylate, etc.);\n* Patients who have used drugs with risks of bleeding and thrombosis within 1 week before surgery, such as oral contraceptives, estrogens, or prothrombin complex concentrates;\n* Patients who have used drugs that can increase hemoglobin levels (such as erythropoietin, EPO) within 4 weeks before screening;\n* 1-Patients who have taken iron supplements within 1 week before surgery or used intravenous iron supplements within 4 weeks before surgery.\n* Patients with mental or neurological diseases, a history of drug abuse, or a history of alcoholism that, in the investigator's opinion, could affect their -participation in the study,specifically, those who consumed more than 14 standard units of alcohol per week within 3 months before screening (1 standard unit equals 14g of alcohol, such as 360ml of beer, 45ml of spirits with 40% alcohol content, or 150ml of wine);\n* Patients who have participated in or are currently participating in other clinical trials within 3 months before screening (participation in a clinical trial is defined as the patient receiving an intervention);\n* Pregnant or lactating women, or patients of childbearing potential who cannot ensure the use of at least one acceptable form of contraception during the study and for 3 months after the end of the study;\n* Patients whom the investigator deems unsuitable for participation in this clinical trial.","70 Years",{"count":101,"type":21},270,[55],"This is a randomized, double-blind, active-controlled, multicenter, phase II clinical study designed to evaluate the efficacy and safety of BT-114143 Injection in the perioperative treatment of unilateral total knee arthroplasty. It is planned to enroll 270 subjects undergoing elective unilateral open total knee arthroplasty. Subjects will be randomly assigned to the BT-114143 high-dose group, BT-114143 low-dose group, or tranexamic acid treatment group in a 1:1:1 ratio. All subjects will receive intravenous injection of BT-114143 or tranexamic acid before and after surgical incision. The total perioperative blood loss in different treatment groups will be evaluated.",[105],"Total Knee Arthroplasty",{"date":85,"type":36},{"date":108,"type":36},"2025-08-27",{"date":110,"type":21},"2026-12-31",{"name":42,"class":43},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":119,"sex":17,"minAge":18,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":44},"100599651","phase-1-a-phase-i-study-of-snh-119014-in-healthy-volunteers-100599651","NCT07087262","A Phase I Study of SNH-119014 in Healthy Volunteers","A Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic of SNH-119014 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy male or female subjects;\n* 18-45 years of age, inclusive;\n* Male subjects with body weight ≥50 kg, female subjects with body weight ≥45 kg; BMI ≥18.5 and ≤28.0 kg\u002Fm2.\n* Must provide written informed consent.\n\nExclusion Criteria:\n\n* History of or current clinically significant circulatory system, endocrine system, nervous system, digestive system, respiratory system, urinary system, ophthalmology, hematology, immunology, psychiatry disorder, as judged by the investigator；\n* Subjects who have undergone major surgery 6 months prior to screening or who plan to undergo surgery during the study period;\n* Clinically significant abnormal physical examination, vital signs, chest X-ray, laboratory tests during the screening period as judged by the investigator;\n* Subjects with QTcF\\>450 ms, or with other ECG clinically significant abnormalities during the screening period as judged by the investigator;\n* Subject has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), treponema pallidum antibody, or human immunodeficiency virus (HIV) antibody at screening;\n* Subjects who have a known chronic liver disease, or who have clinically significant abnormal liver function test results during the screening period;\n* History of urinary system diseases.\n* History of dysphagia or any gastrointestinal disorder affecting drug absorption.\n* History of malignancy.\n* History of severe allergies or allergic to the study drug or any of its components. Serious adverse reaction or hypersensitivity to any drug or the formulation excipients.\n* Failure to follow a consistent diet.\n* Over 5 cups (200 ml per cup) of tea, coffee, or caffeinated beverages were consumed daily during the 3 months prior to screening.\n* Consumption of a specific diet (e.g. grapefruit and grapefruit-containing products, chocolate, any food containing caffeine), or vigorous exercise, or other factors affecting drug absorption, distribution, metabolism, excretion within 48 hours before the dose of study drug.\n* Subjects who have taken any drugs that alter the activity of liver enzymes and\u002For transporters within 28 days prior to screening.\n* Females who are pregnant or lactating and subjects who are unable to use one or more nonpharmacological contraceptives.\n* Subjects who have taken any prescribed or over-the-counter drug or herbal remedies or nutraceutical product within 14 days before the dose of study drug.\n* Subjects who smoked more than 5 cigarettes per day during the 3 months prior to screening, or who cannot accept a smoking ban throughout the study.\n* Alcohol intake \\>14 units per week within 6 months prior to screening (1 unit is equal to 14g of alcohol such as 360mL of beer, 45mL of 40% spirit, 150mL of wine, or a confirmed positive alcohol breath test, or alcohol prohibition is not acceptable throughout the study.\n* History of drug abuse in the past 1 year prior to screening, or a confirmed positive drugs of abuse test result before randomization.\n* Subjects who plan to conceive or donate sperm or eggs during the study or within 3 months after completion of study.\n* Subjects has received study drug in another clinical study within 3 months before the dose of study drug.\n* Subjects who have donated blood or loss ≥400 mL of blood within 3 months before the dose of study drug, or who plan to donate blood or blood components during the study or within 3 months after completion of study.\n* Subjects who have received a live attenuated vaccine within 28 days before the dose of study drug.\n* Subjects who cannot tolerate venipuncture, or those with a history of needle fainting or blood fainting.\n* In the opinion of the investigator, the subject is not suitable for entry into the study.",true,"45 Years",{"count":122,"type":21},96,[24],"SNH-119014 is an oral small-molecule agonist of pyruvate kinase red blood cell isozyme (PKR) being developed for the treatment of hemolytic anemias. This initial study will characterize the safety, tolerability and the pharmacokinetics\u002Fpharmacodynamics (PK\u002FPD) of a single ascending dose and multiple ascending doses of SNH-119014 in the context of Phase 1 studies in healthy volunteers. The effects of food on the absorption of SNH-119014 will also be evaluated in healthy volunteers.",[126],"Hemoglobinopathy","2025-07-23",{"date":129,"type":36},"2025-07-25",{"date":131,"type":36},"2025-06-27",{"date":133,"type":21},"2026-03-28",{"name":42,"class":43},""]